Cancer clinical trials in the region Pays de la Loire

439 currently recruiting clinical trials
Region Pays de la Loire

Phase 3 Prostate cancer #NCT06629779 #2024-511652-40-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Pfizer
Phase 3 Colon cancer Rectal cancer #NCT04120701 #2024-515297-27-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Surgery
Excluded previous treatments at localized stage
Chemotherapy Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
124 recruiting sites
CHU Dijon
Phase 3 Stomach and esophageal cancer #NCT07270991 #2025-522395-92-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Fédération Francophone de Cancérologie Digestive
Phase 3 Lung cancer #NCT06452277 #2024-511319-91-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
14 recruiting sites
Bayer
Phase 3 Lung cancer #NCT05920356 #2022-501863-41-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KRAS G12C
Required PDL1 statuses
PDL1 Negative (< 1%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
27 recruiting sites
Amgen
Phase 3 Sarcoma and GIST #NCT03805022 #2018-000186-36
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
6 recruiting sites
Institut Bergonié
Phase 3 Sarcoma and GIST #NCT06127407 #2023-508507-20-00
Required histologic types
Bone sarcoma
Required histologic sub types
Chondrosarcoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy Targeted therapy
8 recruiting sites
Phase 3 Lung cancer Colon cancer Rectal cancer Pancreas cancer Sarcoma and GIST #NCT06332274 #2023-503316-33-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Soft tissue sarcoma
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy
Required previous treatments at advanced or metastatic stage
Surgery Chemotherapy
Excluded genetic anomalies
EGFR
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Head and neck cancer #NCT07276399 #2025-521917-24-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Janssen
Phase 3 Head and neck cancer #NCT04747054
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx Other
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
20 recruiting sites
UNICANCER